-
Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting
•
Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical data for its paclitaxel polymer micelles will be presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Clinical Data from Retrospective Study in NSCLC TreatmentThe data originates from a retrospective study examining…
-
SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements
•
The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group Limited (HKG: 0512) and WuHan Huihai Pharmaceuticals Co., Ltd. The two companies were found guilty of reaching and implementing a monopoly agreement and abusing their dominant market position in the sales of active pharmaceutical ingredients…
-
Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of its four oncology drugs, including olverembatinib, Bcl-2 inhibitor APG-2575, MDM2-p53 inhibitor APG-115, and FAK/ALK/ROS1 triple inhibitor APG-2449, at an upcoming medical conference. Phase I Study for APG-2449 in Solid TumorsAn open, multicenter, dose escalation, and…
-
Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data
•
The government of Hainan province has entered into a strategic partnership with the National Healthcare Security Administration (NHSA) by signing a memorandum of understanding (MoU). This collaboration aims to enhance the medical insurance industry through the innovative use of real-world data in procurement processes and beyond. Leveraging Real-World Data for…
-
BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene’s research expertise and the productivity of one of the industry’s largest research and development teams. The…
-
Shanghai Market Regulation Bureau Targets Unfair Competition in Pharmaceutical Sector
•
The Shanghai market regulation bureau has released a document aimed at cracking down on unfair competition activities, with a particular focus on commercial bribery in pharmaceutical purchasing and sales, as well as medical equipment procurement. Case 1: Shanghai Fumei Dongjia Pharmacy Bribery IncidentThe bureau has handled a case involving Shanghai…
-
Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma
•
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a phosphatidylinositol 3-kinase (PI3-K) α/δ inhibitor, is set to receive priority review status for the treatment of recurrent/refractory follicular lymphoma (FL) as a third-line or later treatment option. TQ-B3525: A Dual Inhibitor Addressing Drug ResistanceTQ-B3525 is…
